A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

摘要: 1005 Background: E2100, AVADO, and RIBBON-1, three randomized trials in patients with MBC evaluating BV plus first-line chemotherapy regimens (taxane-, anthracycline-, or capecitabine-based), each demonstrated improvement the primary endpoint of progression-free survival (PFS). Although were not designed to show an overall (OS) benefit, it was a secondary all trials. We present meta-analysis OS 2,447 from these using complete data for study. Methods: Kaplan—Meier methodology used estimate median duration PFS OS. Stratified log-rank test assess difference between treatment arms (control vs. BV+chemo). hazard ratio (HR) estimated Cox regression model. Each individual study included as stratification factor stratified analysis. 1-year rate compared normal approximation method. All p-values two-sided tested at type I erro...